Navigation Links
Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:3/1/2011

chief executive officer of Pervasis. "Receiving Orphan Drug Designation in the EU is an important step, as it will help to advance the development process, and enhance our ability to deliver our novel cell-based therapeutic approach to address this significant unmet medical need."

Vascugel has demonstrated proof of concept in two Phase 2 clinical trials involving patients with ESRD who require a permanent arteriovenous (AV) access in order to undergo hemodialysis. In these trials, Vascugel exhibited an excellent safety profile, and encouraging efficacy trends were observed, including improved duration of patency (or unimpeded blood flow) and a delay in time to first intervention as compared to placebo.

In 2009, Pervasis received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Vascugel in patients with ESRD. Pervasis announced last month that the FDA had granted Fast Track review status for Vascugel. Last year, Pervasis reached an agreement with the FDA for a Phase 3 clinical trial of Vascugel under the Agency's Special Protocol Assessment (SPA) procedure, whereby FDA formalized its agreement that the design of the Phase 3 trial was acceptable to support a regulatory submission seeking new drug approval.

Failure of Hemodialysis Access Leads to Poor OutcomesDuring hemodialysis, blood is removed from the body, filtered through a dialyzer, or artificial kidney, and then returned to the body. Patients must undergo a surgical intervention to create a vascular access that enables blood to flow from the body to the dialyzer and back to the body. AV fistulae (created by directly joining an artery and vein) and AV grafts (created using a synthetic tube to join an artery and vein) are the two primary types of hemodialysis access.

Due to an inflammatory cascade triggered by surgical intervention, the vascular access often has difficulty healing, and quickly becomes unusable or clots rapidly, prompting the need for a
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
2. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
5. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
6. Mylan Receives Approval for Generic Version of Neurontin® Capsules
7. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
8. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
9. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
10. Delcath Systems Receives Refusal to File Letter From FDA
11. Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  As the ... of regulations, Ethics & Compliance professionals are placing ... a new survey issued today by LRN, the ... education. An overwhelming majority of respondents expressed that ... most important component of E&C training programs (57%), ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... second quarter ended January 31, 2015 on Thursday, March 12 ... discuss the results at 11:00 AM ET. ... 5 to 10 minutes before the beginning of the call. ... the call will be available from Thursday, March 12, 2015 ...
(Date:3/5/2015)... , March 5, 2015  Medical Diagnostic ... specializes in high complexity, state-of-the-art, automated DNA-based molecular ... Human Papillomavirus (HPV) testing which utilizes cutting edge ... Each year, approximately 12,000 women are diagnosed ... States . Genital Human Papillomaviruses (HPV) are ...
Breaking Medicine Technology:Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
... 16, 2011 Cancer patients in China ... the announcement that a leading cancer center is acquiring ... VAR). This device is the first high dose rate ... leader in radiotherapy systems. Jilin University ...
... 16, 2011 U L ... announced today that it has filed an abbreviated 510(k) application ... label claim to include the management and mitigation of pain. ... a randomized clinical study comparing Altrazeal® to Acquacel® Ag in ...
Cached Medicine Technology:First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4
(Date:3/5/2015)... East Providence, RI (PRWEB) March 05, 2015 ... for a third year in a row to support the ... cancer. The donation covered the purchase of the ‘Think ... Out’ game against Big East Conference opponent DePaul University at ... is pleased to continue our support of the PC women’s ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 In honor ... to shatter myths about drug and alcohol abuse in ... released a Fact Sheet with information on some of ... in 2010 by the National Institute on Drug Abuse, ... alcohol aims to counteract the illusions that teens and ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... the natural products coffee drinks category[1], today unveils its ... West in Anaheim, Calif. Concentrated Cold Brew (CCB) ... Café, which democratizes the next wave of the coffee-taste ... need to become their own baristas. , Califia ...
(Date:3/5/2015)... New York, NY (PRWEB) March 05, 2015 ... NY orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named ... in the New York Metro area. Dr. Glashow has ... in its authoritative guide to the top specialty care ... 2015. , The prestigious Castle Connolly program, which carefully ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Nutrition Leaders, ... products, is pleased to offer reformulated Millennium 500 Creatine ... Millennium 500 is a German grade creatine supplement that ... promote muscle recovery, and aid with overall strength gains ... that acts as a reserve energy source in the ...
Breaking Medicine News(10 mins):Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2
... a study done by Kate Rittenhouse-Olson, Ph.D., the monoclonal antibody ... shown to extend// significantly the survival of mice with human ... antibody inhibits the cancer's spread to the lungs in the ... study were published in the November 2006 issue of Journal ...
... of height which happens as people catch up with age is ... which could have major repercussions on health, increasing the chances of ... of about 3 centimeters or more in height of men as ... compared to men who lose less than a centimeter. This risk ...
... Researchers from University of Queensland believe that the conotoxins ... treatment for sufferers from chronic pain//. This treatment could ... ,Researchers say that the toxin, snail uses ... the severe side effects usually caused by other pain ...
... say that they are not abandoning their quest of finding ... the death of new cholesterol drugs manufactured// by Pfizer. Reducing ... cardiology in recent years, but boosting its counterpart, HDL, also ... market the new drug with Lipitor, a cholesterol-lowering statin that ...
... will now be made more easily available to critically ill ... proposition that will enable patients// who are extremely ill to ... other options. ,The FDA has announced that they ... drugs to be made available to needy individuals .They will ...
... nosed, bleary- eyed Britons, relief from hay fever may ... pill, designed to prevent// allergic reactions like a running nose, itching ... ,The vaccine pill contains small amounts of Timothy grass pollen; main ... weeks before hay fever season. ,This pill follows the ...
Cached Medicine News:Health News:Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies 2Health News:Revolutionary Pill Promises Relief for Hay Fever Sufferers 2
For the quantitative in vitro determination of Transferrin in human serum...
For the quantitative in vitro determination of Transferrin in Serum...
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Medicine Products: